APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
HR 938, the Bringing Low-cost Options and Competition while Keeping Incentives for new Generics (BLOCKING) Act of 2019, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; and HR 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), Part 1-Addressing Supply Shortages, Section 3112, additional manufacturer reporting requirements in response to drug shortages, provisions relating to reporting requirements for pharmaceutical manufacturers; and Federal policy relating to global drug supply chain issues.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.